[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Tvardi Therapeutics Inc (TVRD)

Tvardi Therapeutics Inc (TVRD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,010
  • Shares Outstanding, K 13,339
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,210 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.04

Options Overview Details

View History
  • Implied Volatility 591.12% (-2.47%)
  • Historical Volatility 58.59%
  • IV Percentile 91%
  • IV Rank 39.29%
  • IV High 1,410.62% on 08/03/26
  • IV Low 60.76% on 07/02/26
  • Expected Move (DTE 17) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 414
  • Volume Avg (30-Day) 60
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 1,813
  • Open Int (30-Day) 2,138
  • Expected Range 1.7450 to 1.7450

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.51
  • Number of Estimates 4
  • High Estimate $-0.28
  • Low Estimate $-0.74
  • Prior Year $-0.59
  • Growth Rate Est. (year over year) +13.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.7000 +2.65%
on 08/10/26
2.0900 -16.51%
on 08/03/26
-0.3550 (-16.90%)
since 07/31/26
3-Month
1.5000 +16.33%
on 06/26/26
5.6900 -69.33%
on 07/08/26
-1.4750 (-45.81%)
since 06/01/26
52-Week
1.5000 +16.33%
on 06/26/26
43.6500 -96.00%
on 10/10/25
-28.1750 (-94.17%)
since 08/29/25

Most Recent Stories

More News
Tvardi Therapeutics to Participate in Upcoming Investor Events

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics to Participate in Upcoming Investor Events

HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule...

TVRD : 1.7450 (-3.06%)
Tvardi: Q2 Earnings Snapshot

Tvardi: Q2 Earnings Snapshot

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Reported topline healthy volunteer  results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel,...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation,...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling  More than 70%...

TVRD : 1.7450 (-3.06%)
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and...

TVRD : 1.7450 (-3.06%)

Business Summary

Tvardi Therapeutics Inc. is a privately held, clinical-stage, biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi Therapeutics Inc., formerly known as Cara Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 1.9033
2nd Resistance Point 1.8717
1st Resistance Point 1.8083
Last Price 1.7450
1st Support Level 1.7133
2nd Support Level 1.6817
3rd Support Level 1.6183

See More

52-Week High 43.6500
Fibonacci 61.8% 27.5487
Fibonacci 50% 22.5750
Fibonacci 38.2% 17.6013
Last Price 1.7450
52-Week Low 1.5000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.